Our achievements in research projects made in close collaboration with our partners are published in peer reviewed journals.
News &
European Commission grants orphan drug designation for EVOCellic
Important milestone: EVOMEDIS has received Orphan Drug Designation from the European Medicines Agency (EMA) for its novel cell therapy drug for the treatment of severe burns.
Read More
Kleine Zeitung
Die Behandlung von Verbrennungswunden ist das Spezialgebiet des Start-ups EVOMEDIS, das sich aufgrund der exzellenten Wundtherapie-Expertise in Graz am ZWT angesiedelt hat.
Read More
biomedicines, 2022
Orchestrating the Dermal/Epidermal Tissue Ratio during Wound Healing by Controlling the Moisture Content
Read More
biomedicines, 2021
A 3D In Vitro Model for Burn Wounds: Monitoring of Regeneration on the Epidermal Level
Read More
Burns, 2021
The use of a novel burn dressing out of bacterial nanocellulose compared to the French standard of care in paediatric 2nd degree burns – A retrospective analysis
Read More
jpharmsci, 2021
Current Approaches of Preservation of Cells During (freeze-) Drying
Read More
International wound journal, 2021
Comparison of wound healing and patient comfort in partial-thickness burn wounds treated with SUPRATHEL and epictehydro wound dressings
Read More
Eur. J. Pharm. Sci., 2021
DMSO as new, counterintuitive excipient for freeze-drying human keratinocytes
Read More
Join our open clinical network and profit from our devolpment expertise.